Medicine
Foscavir 6000 mg/250 mL injection
Foscavir 6000 mg/250 mL injection is a prescription medicine containing Foscarnet for intravenous use, marketed by Clinigen, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Protect from excessive heat (above 40°C) and from freezing. If refrigerated or…
Key facts
- Active ingredient (INN)
- Foscarnet
- Brand
- Foscavir
- Strength
- 6000 mg/250 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 10 cartons of 250 mL
- Marketing authorisation holder
- Clinigen
- Manufacturer
- Clinigen
- Origin register
- US FDA, United States
- Storage
- Protect from excessive heat (above 40°C) and from freezing. If refrigerated or exposed to temperatures below the freezing point, precipitation may occur. Store between 20° and 25°C (68° and 77°F). By keeping the bottle or infusion bag at room temperature with repeated shaking, the precipitate can be brought into solution again.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AD01 Foscarnet
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 July 2012
- Identifiers
- RxCUI 855613, 1734377DailyMed set ID a09299d5-9c55-4cef-aed0-3a6a45532289, 90e3da4e-3b1f-428b-99ca-e4bed1c80028NDC 76310-024Application NDA020068
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 September 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Foscarnet 6000 mg/250 mL injection.
Clinical summary
Foscarnet is a pyrophosphate analog DNA polymerase inhibitor indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS), among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Foscarnet for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about FoscarnetFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Foscavir prescribing information (Clinigen) · U.S. National Library of Medicine, DailyMed
Need Foscavir 6000 mg/250 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.